This content is not available in your region

GSK says U.S. FDA wants more information on pulmonary drug

Access to the comments Comments
GSK says U.S. FDA wants more information on pulmonary drug
FILE PHOTO: The GlaxoSmithKline (GSK) logo. March 21, 2018. REUTERS/Loriene Perera/File Photo   -   Copyright  Loriene Perera(Reuters)
Text size Aa Aa

LONDON (Reuters) – GlaxoSmithKline <GSK.L> said on Friday that U.S. health authorities had asked for more information about its Nucala drug for use in combating chronic obstructive pulmonary disease (COPD).

GSK said it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its application for mepolizumab – the generic name for Nucala – as an add-on treatment to inhaled corticosteroid-based maintenance treatment.

“The CRL states that more clinical data are required to support an approval,” the company said in a statement. “GSK will work closely with the FDA to determine the appropriate next steps for the supplementary biologics licence application.”

The FDA has previously cleared Nucala to treat severe asthma.

(Writing by William Schomberg; Editing by Leslie Adler)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.